Business Context and Reporting Period
This Form 8-K Current Report for Anavex Life Sciences Corp. covers material events occurring between January 12, 2009, and March 20, 2009, with the report dated April 3, 2009. The company, incorporated in Nevada with offices in Greece and Switzerland, is a biotechnology firm focused on drug candidates for neurological diseases. The filing details the entry into material definitive agreements, including convertible loans, consulting contracts, and private placements of equity securities.
Key Financial Metrics and Capital Activities
The filing does not provide standard financial statements (revenue, profit, or cash flow) but details specific capital raising and debt activities:
- Convertible Loans: The company secured three unsecured, 0% interest convertible loans totaling $1,919,418.
- Jan 12, 2009: $150,000 (for general working capital).
- Feb 2, 2009: $1,669,418 (for payment of outstanding promissory notes).
- Mar 16, 2009: $100,000 (for Anavex 2-73 Phase 1 trial scale-up and working capital).
- Private Placement Proceeds: The company raised gross proceeds of $224,883 through the sale of units (common stock + warrants).
- Mar 6, 2009: $200,583 from 89,148 units sold to five purchasers.
- Mar 20, 2009: $24,300 from 10,800 units sold to one purchaser.
- Equity Issuance for Services: Issued 2,500 shares of common stock on March 20, 2009, as a deferral payment for services to settle outstanding accounts.
- Stock Options Granted:
- 50,000 options to Dr. Mark A. Smith (exercise price $2.75).
- 5,000 options to Tariq Arshad (exercise price $2.50).
Material Changes and Agreements
The primary material changes involve the company's capital structure and operational partnerships:
- Debt Structure: The company entered into three convertible loan agreements. All loans are convertible into units at $2.25 per unit. Each unit comprises one share of common stock and one warrant exercisable at $4.00 for 12 months. The loans are due in full one year from the advancement date.
- Consulting Partnerships:
- Agreement with Dr. Mark A. Smith for consulting on disease-modifying treatments for neurological diseases. Compensation includes $2,000/month, $250 per speaking engagement, and 50,000 stock options.
- Agreement with Tariq Arshad for strategic development in biotech. Compensation includes 5,000 fully vested stock options.
- Capital Raising: Execution of private placements outside the United States to fund research and development (R&D) and working capital.
Outlook, Risks, and Management Commentary
Use of Proceeds: Management intends to utilize the raised funds for general working capital, repayment of outstanding promissory notes, and specifically for the scale-up production of Anavex 2-73 for Alzheimer's Phase 1 trials.
Risks and Contingencies:
- Dilution Risk: The convertible loans and private placements introduce significant potential dilution if converted or exercised. The conversion price ($2.25) and warrant exercise price ($4.00) are fixed.
- Liquidity: The company is actively raising capital to pay outstanding notes and fund operations, indicating a reliance on external financing.
- Regulatory Status: Securities issued (options and private placement units) were unregistered, relying on exemptions under Section 4(2) of the Securities Act, Rule 506 of Regulation D, and Regulation S. These securities may not be offered or sold in the United States absent registration.
Investor Verification Checklist
- Verify the total outstanding debt and the specific terms of the "outstanding promissory notes" mentioned as being paid by the February loan.
- Confirm the current cash position and runway given the reliance on convertible debt and private placements for working capital.
- Assess the progress of the Anavex 2-73 Phase 1 trials for Alzheimer's, as this is a primary use of funds.
- Review the total number of shares outstanding and the potential dilution impact from the 100,000+ options granted and the convertible loan units.
- Check for any subsequent filings regarding the repayment or conversion of the $1.9M in convertible loans.